Comparative Pharmacology
Head-to-head clinical analysis: DILTZAC versus PROCARDIA XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILTZAC versus PROCARDIA XL.
DILTZAC vs PROCARDIA XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries and decreased myocardial contractility and conduction velocity.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Oral: 30-120 mg 3-4 times daily; maximum 480 mg/day. IV: 0.25 mg/kg over 2 min, then 0.35 mg/kg after 15 min if needed; continuous infusion 5-15 mg/hour.
30-90 mg orally once daily, extended-release tablet.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (healthy adults). Prolonged in elderly (6-8 hours) and in hepatic impairment (10-12 hours).
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Renal: 60-70% as metabolites, 2-4% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker